Trials / Completed
CompletedNCT01310166
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 447 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fingolimod |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2011-03-08
- Last updated
- 2016-11-18
Locations
61 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01310166. Inclusion in this directory is not an endorsement.